Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$65.43
+3.7%		$53.87
$14.03
▼
$72.51
$3.27B2.381.50 million shs1.50 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$10.41
-2.5%		$13.98
$8.80
▼
$23.29
$908.94M1.081.99 million shs2.41 million shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$26.85
-7.3%		$35.83
$24.51
▼
$42.49
$3.58BN/A1.37 million shs1.19 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$43.11
-2.1%		$43.61
$29.45
▼
$60.91
$3.54B1.951.56 million shs760,402 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
+3.66%+2.57%+30.18%+119.93%+350.31%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-2.53%-4.93%-16.79%-47.85%-2.35%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-7.25%-6.96%-27.20%-10.23%+2,684,999,900.00%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.07%-3.45%+5.48%-27.56%+26.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$65.43
+3.7%		$53.87
$14.03
▼
$72.51
$3.27B2.381.50 million shs1.50 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$10.41
-2.5%		$13.98
$8.80
▼
$23.29
$908.94M1.081.99 million shs2.41 million shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$26.85
-7.3%		$35.83
$24.51
▼
$42.49
$3.58BN/A1.37 million shs1.19 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$43.11
-2.1%		$43.61
$29.45
▼
$60.91
$3.54B1.951.56 million shs760,402 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
+3.66%+2.57%+30.18%+119.93%+350.31%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-2.53%-4.93%-16.79%-47.85%-2.35%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-7.25%-6.96%-27.20%-10.23%+2,684,999,900.00%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.07%-3.45%+5.48%-27.56%+26.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.38
Hold$54.00-17.47% Downside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.43
Hold$28.50173.78% Upside
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
2.71
Moderate Buy$41.6755.18% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.64
Moderate Buy$55.7829.38% Upside

Current Analyst Ratings Breakdown

Latest MLTX, VCYT, CDNA, and PBLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
CareDx, Inc. stock logo
CDNA
CareDx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
10/5/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$50.00
10/2/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D+) ➝ Sell (D)
10/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
10/2/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
9/24/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C+) ➝ Hold (C)
9/24/2026
CareDx, Inc. stock logo
CDNA
CareDx
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$60.00 ➝ $74.00
9/18/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
9/16/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/15/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M8.91$0.01 per share9,690.79$5.89 per share11.11
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M6.70$1.46 per share29.55$16.57 per share2.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.07371.29103.86N/A24.23%2.87%2.17%11/3/2026 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$145.89M-$2.13N/AN/AN/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.4128.9627.99N/A20.37%9.26%8.61%11/3/2026 (Estimated)

Latest MLTX, VCYT, CDNA, and PBLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.77N/AN/AN/AN/AN/A
11/3/2026Q3 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2552N/AN/AN/A$121.95 millionN/A
11/3/2026Q3 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4111N/AN/AN/A$147.16 millionN/A
8/13/2026Q2 2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$0.16-$2.32-$2.16-$2.32N/A$0.15 million
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
7/30/2026Q2 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2321$0.37+$0.1379$2.07$114.05 million$131.95 million
7/30/2026Q2 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4103$0.54+$0.1297$0.31$144.59 million$150.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.58
4.51
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
17.91
17.91
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.16
8.80

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
76551.73 million50.49 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
145123.53 millionN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
75580.39 million79.11 millionOptionable

Recent News About These Companies

Veracyte, Inc. (NASDAQ:VCYT) Stock Rated "Moderate Buy" by Sell-Side Analysts
October 11 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107044
Veracyte, Inc. (NASDAQ:VCYT) Stock Has Average Target Price of $55.78
October 11 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-veracyte-inc-nasdaq-vcyt-stock-has-average-target-price-of-5578-2026-10-11/
Veracyte (NASDAQ:VCYT) Stock Dropped to Buy by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104417
Veracyte (NASDAQ:VCYT) Stock Rating Lowered by Wall Street Zen
October 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-veracyte-nasdaq-vcyt-stock-rating-lowered-by-wall-street-zen-2026-10-10/
Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/veracyte-vcyt-stock-still-looks-051324851.html
Congress Asset Management Co. Makes New Investment in Veracyte, Inc. $VCYT
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-congress-asset-management-co-makes-new-investment-in-veracyte-inc-vcyt-2026-10-06/
Veracyte stock falls 4.64 percent as Decipher data draw focus
October 6, 2026  |  ad-hoc-news.deA
Veracyte (NASDAQ:VCYT) Stock Falls 4.3% - Should You Sell?
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-veracyte-nasdaq-vcyt-stock-falls-43-should-you-sell-2026-10-06/
Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/veracyte-vcyt-down-9-0-110925849.html
Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/veracyte-vcyt-could-22-undervalued-160913042.html
Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-veracyte-vcyt-change-prostate-200928762.html
Veracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...
September 29, 2026  |  marketscreener.comM
Veracyte's Decipher Test Predicts Hormone Therapy Benefit In Phase 3 Prostate Cancer Analysis
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694894/veracyte-s-decipher-test-predicts-hormone-therapy-benefit-in-phase-3-prostate-cancer-analysis.aspx
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
September 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/phase-iii-trial-demonstrates-veracyte-s-decipher-prostate-test-predicts-benefit-from-adding-hormone-therapy-to-radiation-1036581190
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370777/0/en/phase-iii-trial-demonstrates-veracyte-s-decipher-prostate-test-predicts-benefit-from-adding-hormone-therapy-to-radiation.html
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
September 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/25/3369344/0/en/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026.html
Veracyte (NASDAQ:VCYT) Stock Falls 5.7% - Time to Sell?
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-veracyte-nasdaq-vcyt-stock-falls-57-time-to-sell-2026-09-25/
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?
September 25, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995946/veracyte-vcyt-surges-10-8-is-this-an-indication-of-further-gains?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2995946
Veracyte (NASDAQ:VCYT) Shares Up 6.5% - Still a Buy?
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-veracyte-nasdaq-vcyt-shares-up-65-still-a-buy-2026-09-24/
John Leite Sells 4,015 Shares of Veracyte (NASDAQ:VCYT) Stock
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-john-leite-sells-4015-shares-of-veracyte-nasdaq-vcyt-stock-2026-09-22/
Veracyte Acquires Convergent Genomics For Up To $180 Million To Add Urinary Tumor DNA Bladder Cancer Platform
September 21, 2026  |  pulse2.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

CareDx stock logo

CareDx NASDAQ:CDNA

$65.43 +2.31 (+3.66%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$65.91 +0.48 (+0.74%)
As of 08:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.41 -0.27 (-2.53%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$10.47 +0.06 (+0.57%)
As of 08:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Parabilis Medicines stock logo

Parabilis Medicines NASDAQ:PBLS

$26.85 -2.10 (-7.25%)
As of 10/13/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$43.11 -0.91 (-2.07%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$43.40 +0.29 (+0.66%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas